BioCentury
ARTICLE | Company News

OGS's Vevesca MAA accepted for review

July 12, 2001 7:00 AM UTC

Oxford GlycoSciences (LSE:OGS; OGSI) said the EMEA accepted for review the MAA for its Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor ( OGT 918) to treat Gaucher disease. The submi...